1. Cell Cycle/DNA Damage
    Epigenetics
  2. PARP

PARP

PARP is a family of proteins involved in a number of cellular processes involving mainly DNA repair and programmed cell death. The PARP family comprises 17 members. They have all very different structures and functions in the cell. PARP1, PARP2, VPARP (PARP4), Tankyrase-1 and -2 (PARP-5a or TNKS, and PARP-5b or TNKS2) have a confirmed PARP activity. Others include PARP3, PARP6, TIPARP (or PARP7), PARP8, PARP9, PARP10, PARP11, PARP12, PARP14, PARP15, and PARP16. PARP is found in the cell’s nucleus. The main role is to detect and signal single-strand DNA breaks (SSB) to the enzymatic machinery involved in the SSB repair.

PARP Related Products (36):

Cat. No. Product Name Effect Purity
  • HY-10162
    Olaparib Inhibitor 99.71%
    Olaparib is a potent PARP inhibitor with IC50 of 5 and 1 nM for PARP-1 and PARP-2, respectively.
  • HY-16106
    BMN-673 Inhibitor 99.83%
    BMN-673 is a novel PARP1/2 inhibitor with IC50 of 0.57 nM for PARP1.
  • HY-15147
    XAV-939 Inhibitor 98.04%
    XAV-939 is a selective Wnt pathway β-catenin-mediated transcription inhibitor and axin stabilizing agent with IC50 values of 5 and 2 nM for the inhibition of TNKS1 and TNKS2, respectively.
  • HY-10619
    MK-4827 Inhibitor 99.88%
    MK-4827 is an excellent PARP1 and PARP2 inhibitor with IC50 of 3.8 and 2.1 nM, respectively.
  • HY-10129
    Veliparib Inhibitor >98.0%
    Veliparib is a potent PARP inhibitor, inhibiting PARP1 and PARP2 with Kis of 5.2 and 2.9 nM, respectively.
  • HY-100225
    ME0328 Inhibitor 99.34%
    ME0328 is a potent and selective ARTD3/PARP3 inhibitor with an IC50 of 0.89±0.28 μM.
  • HY-108413
    Talazoparib tosylate Inhibitor 99.74%
    Talazoparib tosylate (BMN 673ts) is a novel, potent and orally available PARP1/2 inhibitor with an IC50 of 0.57 nM for PARP1.
  • HY-100863
    BRCA1-IN-1 Inhibitor
    BRCA1-IN-1 is a novel small-molecule-like BRCA1 inhibitor with IC50 and Ki of 0.53 μM and 0.71 μM, respecrively.
  • HY-10617
    Rucaparib phosphate Inhibitor 99.89%
    Rucaparib (phosphate) is an inhibitor of PARP with Ki of 1.4 nM for PARP1 in a cell-free assay, and also shows binding affinity to eight other PARP domains.
  • HY-B0150
    Nicotinamide Inhibitor >98.0%
    Nicotinamide is a water-soluble vitamin, an active component of coenzymes NAD and NADP, and acts as poly (ADP-ribose) polymerase (PARP) inhibitor.
  • HY-13688
    PJ34 hydrochloride Inhibitor
    PJ34 hydrochloride is a potent specific inhibitor of PARPl/2 with IC50 of 110 nM and 86 nM, respectively.
  • HY-10619B
    MK-4827 tosylate Inhibitor 99.52%
    MK-4827 tosylate is an excellent PARP1 and PARP2 inhibitor with IC50 of 3.8 and 2.1 nM, respectively.
  • HY-10130
    Veliparib dihydrochloride Inhibitor 99.62%
    Veliparib (dihydrochloride) is a potent inhibitor of PARP1 and PARP2 with Ki of 5.2 nM and 2.9 nM in cell-free assays, respectively.
  • HY-104044
    Pamiparib Inhibitor 99.91%
    Pamiparib is a PARP inhibitor which can be used for the treatment of various cancers including the solid tumor, extracted from patent WO 2013097225 A1.
  • HY-12418
    E7449 Inhibitor >99.0%
    E7449 is a potent PARP1 and PARP2 inhibitor and also inhibits TNKS1 and TNKS2, with IC50s of 2.0, 1.0, ∼50 and ∼50 nM for PARP1, PARP2, TNKS1 and TNKS2, respectively, using 32P-NAD+ as substrate.
  • HY-13536
    AZD-2461 Inhibitor 98.39%
    AZD-2461 is a potent PARP inhibitor, with IC50s of 5 nM, 2 nM and 200 nM for PARP1, PARP2 and PARP3, respectively.
  • HY-102003
    Rucaparib Camsylate Inhibitor 99.30%
    Rucaparib is an inhibitor of PARP with a Ki of 1.4 nM for PARP1, and also shows binding affinity to eight other PARP domains.
  • HY-18954
    NMS-P118 Inhibitor 99.08%
    NMS-P118 is a potent, orally available, and highly selective PARP-1 Inhibitor for cancer therapy.
  • HY-12015
    BSI-201 Inhibitor 99.65%
    BSI-201 is an irreversible inhibitor of PARP1, used in the research of triple negative breast cancer.
  • HY-12975
    AZ6102 Inhibitor 99.65%
    AZ6102 is a potent dual TNKS1 and TNKS2 inhibitor, with IC50s of 3 nM and 1 nM, respectively, and alao has 100-fold selectivity against other PARP family enzymes, with IC50s of 2.0 μM, 0.5 μM, and >3 μM, for PARP1, PARP2, and PARP6, respectively.